Reading the tape
NASDAQ: TMCI
Treace Medical Concepts, Inc.
Healthcare · Medical - Devices
Market Cap
$118.56M
52w High
$7.78
52w Low
$1.17
P/E
-1.98
Volume
233.63K
Outstanding Shares
64.78M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -75%Revenue (TTM): 1.59%FCF (TTM): 39.53%P/S: 0th pct
What changed
The stock fell 75% over the last year. Revenue grew 1.59% over the trailing twelve months. Operating margin moved from -26.6% to -25.46%. Free cash flow grew 39.53% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -25.46%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States.
CEOJohn T. Treace
SectorHealthcare
IndustryMedical - Devices
Employees477
IPO dateApr 23, 2021
Valuation
Forward P/E—
EV/EBITDA-3.67
Enterprise value$158.28M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-9.01%
Gross margin79.81%▼0.70%vs FY2024
Operating margin-25.46%▲4.28%vs FY2024
ROE-67.56%▼36.83%vs FY2024
Analyst consensus
RatingHold
Target price$3.00▲63.93%
2
Buy
6
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 8, 2026
Q2 FY26 · EPS est -$0.31 · Revenue est $45.96M
View